CA2467731A1 - Conjugues de l'hormone de croissance humaine chimiquement modifiee - Google Patents

Conjugues de l'hormone de croissance humaine chimiquement modifiee Download PDF

Info

Publication number
CA2467731A1
CA2467731A1 CA002467731A CA2467731A CA2467731A1 CA 2467731 A1 CA2467731 A1 CA 2467731A1 CA 002467731 A CA002467731 A CA 002467731A CA 2467731 A CA2467731 A CA 2467731A CA 2467731 A1 CA2467731 A1 CA 2467731A1
Authority
CA
Canada
Prior art keywords
conjugate
hgh
group
peg
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002467731A
Other languages
English (en)
Inventor
Rory F. Finn
Wei Lao
Ned R. Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2467731A1 publication Critical patent/CA2467731A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une hormone de croissance humaine (hGH) chimiquement modifiée obtenue par la liaison d'un polymère soluble dans l'eau à une protéine. La protéine chimiquement modifiée selon la présente invention peut avoir une activité hGH de durée plus longue que celle de la hGH modifiée, ce qui permet d'obtenir une dose réduite et des opportunités de calendrier.
CA002467731A 2001-11-20 2002-11-20 Conjugues de l'hormone de croissance humaine chimiquement modifiee Abandoned CA2467731A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
US60/331,907 2001-11-20
PCT/US2002/037270 WO2003044056A2 (fr) 2001-11-20 2002-11-20 Conjugues de l'hormone de croissance humaine chimiquement modifiee

Publications (1)

Publication Number Publication Date
CA2467731A1 true CA2467731A1 (fr) 2003-05-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002467731A Abandoned CA2467731A1 (fr) 2001-11-20 2002-11-20 Conjugues de l'hormone de croissance humaine chimiquement modifiee

Country Status (25)

Country Link
EP (1) EP1453859A2 (fr)
JP (2) JP2005525302A (fr)
KR (2) KR20050044858A (fr)
CN (1) CN1608079A (fr)
AP (1) AP2004003050A0 (fr)
AU (1) AU2002356990A1 (fr)
BR (1) BR0214451A (fr)
CA (1) CA2467731A1 (fr)
CO (1) CO5580794A2 (fr)
EA (2) EA008505B1 (fr)
EC (1) ECSP045114A (fr)
GE (1) GEP20063860B (fr)
HR (1) HRP20040448A2 (fr)
HU (1) HUP0500997A2 (fr)
IL (1) IL162031A0 (fr)
IS (1) IS7268A (fr)
MA (1) MA27544A1 (fr)
MX (1) MXPA04004809A (fr)
NO (1) NO20042182L (fr)
OA (1) OA13063A (fr)
PL (1) PL374354A1 (fr)
RS (1) RS53104A (fr)
TN (1) TNSN04090A1 (fr)
WO (1) WO2003044056A2 (fr)
ZA (1) ZA200403907B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (fr) * 2001-12-11 2006-05-17 Sun Bio Inc Nouveaux aldehydes de polyethyleneglycol monofonctionnels
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DK3025726T3 (da) * 2002-01-18 2019-12-09 Biogen Ma Inc Polyalkylenpolymerforbindelser og anvendelser deraf
EP1591467A1 (fr) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugue d un polyethylene glycol comprenant un group terminal alcanal et un hormone de croissance humaine
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035553A2 (fr) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugaison de peptides
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
JP2008511610A (ja) * 2004-08-31 2008-04-17 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
AU2005323106B2 (en) * 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
WO2006084888A2 (fr) 2005-02-10 2006-08-17 Novo Nordisk A/S Hormones de croissance pegylees a leur extremite c
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
CN101268098A (zh) * 2005-08-30 2008-09-17 诺沃-诺迪斯克保健股份有限公司 聚乙二醇化生长激素的液体制剂
SI1954710T1 (sl) 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
WO2008003750A2 (fr) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag Nouveaux conjugués de protéines et leurs procédés de préparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
WO2008049920A2 (fr) 2006-10-26 2008-05-02 Novo Nordisk A/S Variantes il-21
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
JP5458416B2 (ja) * 2008-04-03 2014-04-02 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽－聚合物綴合物
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
CA2747825A1 (fr) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Composes stables d'hormone de croissance
EP2461831B1 (fr) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Hormones de croissance ayant une efficacité in vivo prolongée
CA2783296C (fr) 2009-12-15 2019-01-15 Ascendis Pharma As Composition d'hormone de croissance
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
EP2446898A1 (fr) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
EP2981282B1 (fr) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Formulation d'un composé d'hormone de croissance
CA2964390A1 (fr) 2014-11-06 2016-05-12 Pharmaessentia Corporation Regime posologique pour l'interferon pegyle
ES2947818T3 (es) 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Nuevos profármacos poliméricos de la HCh
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
MX391071B (es) * 2015-03-11 2025-03-21 Nektar Therapeutics Conjugados de un resto de il-7 y un polímero.
NZ740534A (en) 2015-09-18 2019-07-26 Univ Miyazaki Long-acting adrenomedullin derivative
EP3934625A1 (fr) 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Formes posologiques d'hormone de croissance à action prolongée ayant une efficacité supérieure à une dose de somatropine quotidienne
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0458064T3 (da) * 1990-05-04 1998-04-27 American Cyanamid Co Stabilisering af somatotropiner ved modificering af cysteinrester
WO1992016555A1 (fr) * 1991-03-18 1992-10-01 Enzon, Inc. Conjuges de polypeptides et de glycopolypeptides associes a des polymeres, contenant de l'hydrazine
WO1993000109A1 (fr) * 1991-06-28 1993-01-07 Genentech, Inc. Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
HK1049673A1 (zh) * 1999-01-29 2003-05-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
WO2002055532A2 (fr) * 2001-01-11 2002-07-18 Maxygen Aps Molecules d'hormone de croissance ameliorees

Also Published As

Publication number Publication date
CO5580794A2 (es) 2005-11-30
AP2004003050A0 (en) 2004-06-30
ECSP045114A (es) 2004-07-23
AU2002356990A1 (en) 2003-06-10
NO20042182L (no) 2004-08-11
ZA200403907B (en) 2007-12-27
MA27544A1 (fr) 2005-10-03
PL374354A1 (en) 2005-10-17
HRP20040448A2 (en) 2006-02-28
HUP0500997A2 (en) 2007-11-28
WO2003044056A3 (fr) 2003-08-21
JP2006321808A (ja) 2006-11-30
JP2005525302A (ja) 2005-08-25
OA13063A (en) 2006-11-10
EP1453859A2 (fr) 2004-09-08
GEP20063860B (en) 2006-06-26
BR0214451A (pt) 2006-05-30
MXPA04004809A (es) 2004-08-11
WO2003044056A2 (fr) 2003-05-30
IL162031A0 (en) 2005-11-20
EA008505B1 (ru) 2007-06-29
KR20050044858A (ko) 2005-05-13
IS7268A (is) 2004-05-17
EA200700431A1 (ru) 2008-02-28
KR20070072924A (ko) 2007-07-06
CN1608079A (zh) 2005-04-20
EA200400565A1 (ru) 2005-06-30
RS53104A (sr) 2006-10-27
TNSN04090A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
AU2002356990A1 (en) Chemically-modified human growth hormone conjugates
US20030171285A1 (en) Chemically-modified human growth hormone conjugates
EP1715887B1 (fr) Conjugues de l'hormone de croissance humaine monopegyles sur le plan n-terminal, procede de preparation et l'utilisation desdits conjugues
EP1789092A2 (fr) Conjugués de l'hormone de croissance humaine avec du polyéthylèneglycol ramifié à l'aide de glycérol, procédé de sa préparation, et méthode de son utilisation.
US20040127417A1 (en) N-terminally monopegylated human growth hormone conjugates and process for their preparation
US20040038892A1 (en) Chemically-modified human growth hormone conjugates
WO2006102659A2 (fr) Conjugues d'un fragment de hgh et d'un polymere
US20090203589A1 (en) Chemically modified human growth hormone receptor antagonist conjugates
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬
HK1072058A (en) Chemically-modified human growth hormone conjugates
HK1104913A (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
MXPA06008888A (en) N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued